NCT04971226 · OUTCOME

PK of Asciminib: Tmax

A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP · Source last updated 2026-08-28

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: MEDIAN
Unit: Hour (hr)
Interval / dispersion: Full Range
Time frame: Week 2 (0 hours (h) pre-dose, 1h, 2h, 3h, 4h, 6h, 8h and 12h post dose)

What was measured

Tmax is the time to reach maximum (peak) plasma drug concentration after dose administration (time)

Analysis population: Full PK samples were collected at Week 2

Patients took asciminib 80 mg QD under fasting conditions on ongoing basis.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Asciminib (All Asciminib)	26

Source class 1

Values in Hour (hr) · Interval/dispersion: Full Range
Group	Value	Spread	Lower	Upper	Comment
Asciminib (All Asciminib)	2.00	Not reported	0.883	3.18	Not reported

Complete source fields

classes

denoms

description

Tmax is the time to reach maximum (peak) plasma drug concentration after dose administration (time)

dispersion Type

Full Range

groups

param Type

MEDIAN

population Description

Full PK samples were collected at Week 2

reporting Status

POSTED

time Frame

Week 2 (0 hours (h) pre-dose, 1h, 2h, 3h, 4h, 6h, 8h and 12h post dose)

title

PK of Asciminib: Tmax

type

SECONDARY

unit Of Measure

Hour (hr)

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice